Silexion Therapeutics (NASDAQ:SLXN) Lowered to Hold Rating by Maxim Group

Silexion Therapeutics (NASDAQ:SLXN) was downgraded by equities research analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Silexion Therapeutics Stock Up 15.0%

NASDAQ:SLXN opened at $1.84 on Wednesday. Silexion Therapeutics has a 52 week low of $1.50 and a 52 week high of $223.60. The firm has a 50 day moving average of $3.17 and a 200 day moving average of $10.12. The stock has a market capitalization of $772,800.00, a price-to-earnings ratio of -0.02 and a beta of -0.26.

Silexion Therapeutics (NASDAQ:SLXN) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($12.90) by $12.05. As a group, analysts expect that Silexion Therapeutics will post -45.5 EPS for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.